Metropolis Healthcare reported a 26% year-on-year rise in profit after tax (PAT) to ₹56.9 crore for the first quarter of FY27, driven by robust volume growth and significant operating leverage. Revenue from operations expanded by 17% to ₹450.2 crore, while EBITDA grew by 27% to ₹113.2 crore. The strong financial performance reflects the company’s successful execution of its "Metropolis 3.0" strategy, emphasizing technology integration, scientific differentiation, and network expansion in Tier-2 and Tier-3 cities. Management reaffirmed its revenue growth outlook of 14% to 15% for the current financial year.

The unaudited consolidated financial results were disclosed on August 4, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The earnings conference call was held on August 5, 2026, led by Executive Chairperson Ameera Shah, Managing Director Surendran Chemmenkotil, Chief Financial Officer Sameer Patel, and Chief Marketing Officer Mohan Menon. The transcript was subsequently filed with BSE Limited and NSE India on August 10, 2026.

Financial Performance

Revenue from operations reached ₹450.2 crore in Q1FY27, up from ₹386.1 crore in the corresponding period of the previous year. EBITDA expanded significantly by 27% to ₹113.2 crore, leading to an EBITDA margin improvement of 210 basis points to 25.2%, up from 23.1%. PAT margin also widened to 12.6% from 11.7%. Despite a decline in other income to ₹5.1 crore from ₹7.5 crore and an increase in finance costs to ₹8.3 crore from ₹4.6 crore, the bottom line remained resilient due to strong operational efficiency.

Operational Drivers

Operational metrics reflected sustained demand across all segments. Patient volume grew by 10% year-on-year to 3.7 million, while test volume increased by 11% to 7.8 million. Revenue per Patient (RPP) rose 6% to ₹1,219, and Revenue per Test (RPT) improved by 5% to ₹575. Management highlighted that this revenue growth was achieved without implementing any price hikes since January 2025, relying instead on organic volume expansion and a richer test mix. B2C revenue expanded 18% to ₹257 crore, driven by brand pull and digital engagement, whereas B2B revenue increased 15% to ₹193 crore due to a broader clinician network.

Segment-wise, TruHealth revenue grew 22% to ₹81 crore, representing 18% of the segment mix. Premium TruHealth packages saw over 50% growth, while radiology-integrated wellness packages increased by more than 40%. Specialty revenue rose 17% to ₹178 crore, accounting for 40% of the mix. Geographically, Tier III cities emerged as the fastest-growing markets with revenue increasing around 25% year-on-year, outpacing Tier II (14%) and Tier I cities (11%).

Strategic Initiatives and Guidance

The company’s service network expanded to 5,003 points, an 8% YoY increase, with 295 new service points added in Q1FY27 despite the rationalisation of 318 non-productive centres. Management aims to add approximately 400 to 500 new centers in Tier 2 and Tier 3 towns this year, targeting a center-to-laboratory ratio of about 1-to-30 by year-end. Capital expenditure is anticipated to be approximately ₹65 crore for the current year, consistent with the previous year's spending.

On margins, EBITDA margin is projected to improve by 100 to 150 basis points this financial year, with a target of 27% to 28% over the current and next year. The integration of Core Diagnostics, acquired in March 2025, continues to strengthen the company’s genomics platform and North India presence, which now contributes 18% of total revenue. North India has emerged as the fastest-growing region, supported by deep clinician relationships and advanced testing capabilities.

What the Numbers Show

The divergence between revenue growth (16.6%) and EBITDA growth (27.1%) highlights significant operating leverage, with EBITDA margin expanding by 210 basis points to 25.2%. The disproportionate growth in Tier III cities (25%) compared to Tier I (11%) indicates a structural shift in the company's revenue base towards lower-competition markets. The decline in other income and rise in finance costs were fully offset by core operational efficiencies, demonstrating the quality of earnings. Furthermore, the absence of price increases despite inflationary pressures underscores the strength of volume-driven growth and market share gains.

Metropolis Healthcare reported a consolidated net profit of ₹568.83 million for the quarter ended June 30, 2026, up 25.7% from ₹452.45 million in the same period last year. Revenue from operations increased 16.6% year-on-year to ₹4,502.15 million, reflecting continued expansion in its pathology services business. The company’s standalone net profit for the quarter stood at ₹505.83 million, compared to ₹355.82 million in Q1FY25.

The Board of Directors, meeting on August 04, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee on the same date and subjected to a limited review by the statutory auditors, B S R & Co. LLP. The Board also noted that the sale and transfer of the External Quality Assessment Services Business to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary, is now expected to take an additional two months beyond the original six-month timeline set in the February 04, 2026 Business Transfer Agreement.

Financial Performance

Consolidated revenue from operations reached ₹4,502.15 million, up from ₹3,860.63 million in Q1FY25. Total expenses rose to ₹3,776.05 million from ₹3,323.49 million in the prior year period. Employee benefits expense, the largest cost component, increased to ₹1,069.76 million from ₹922.79 million. Other expenses stood at ₹1,386.15 million, up from ₹1,193.04 million. The company recorded a profit before tax of ₹777.12 million, compared to ₹612.30 million in Q1FY25.

Standalone revenue from operations was ₹3,722.84 million, up from ₹3,232.69 million in Q1FY25. Standalone profit before tax was ₹663.76 million, compared to ₹473.84 million in the prior year. Basic earnings per share for the consolidated entity were ₹2.73, up from ₹2.17 in Q1FY25.

Operational Updates

The company continues to operate under a single reportable segment: Pathology service. During the quarter, the Nomination and Remuneration Committee approved the grant of 14,236 Restricted Stock Units (RSUs) under the Metropolis Restrictive Stock Unit Plan — 2025 and 2,12,345 Employee Stock Options under the Metropolis Employees Stock Option Plan — 2025. Additionally, 4,200 RSUs were allotted under the Metropolis Restrictive Stock Unit Plan — 2020.

The financial results reflect the impact of three business acquisitions completed in FY25: Dapic Metropolis Healthcare Private Limited (₹346.10 million), Scientific Metropolis Pathology Private Limited (₹645.00 million), and Dr. RS Patil's Ambika Pathology Laboratory (₹170.00 million). These acquisitions have been fully integrated into the consolidated results for Q1FY26.

What the Numbers Show

Revenue growth outpaced expense growth, leading to an expansion in pre-tax margins. Consolidated profit before tax grew 27.0% YoY, slightly higher than the 16.6% revenue growth, indicating operational leverage. However, employee benefits and other expenses saw significant increases, suggesting rising input costs or wage pressures. The delay in the External Quality Assessment Services Business transfer may impact short-term operational efficiency but keeps the business within the consolidated group structure longer than initially planned.